233 related articles for article (PubMed ID: 35891187)
1. Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers.
Zhang H; Wu Z; Hu D; Yan M; Sun J; Lai J; Bai L
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891187
[TBL] [Abstract][Full Text] [Related]
2. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.
Bluemel C; Hausmann S; Fluhr P; Sriskandarajah M; Stallcup WB; Baeuerle PA; Kufer P
Cancer Immunol Immunother; 2010 Aug; 59(8):1197-209. PubMed ID: 20309546
[TBL] [Abstract][Full Text] [Related]
3. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
[TBL] [Abstract][Full Text] [Related]
4. Chondroitin Sulphate Proteoglycan 4 (NG2/CSPG4) Localization in Low- and High-Grade Gliomas.
Mellai M; Annovazzi L; Bisogno I; Corona C; Crociara P; Iulini B; Cassoni P; Casalone C; Boldorini R; Schiffer D
Cells; 2020 Jun; 9(6):. PubMed ID: 32599896
[TBL] [Abstract][Full Text] [Related]
5. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.
Ilieva KM; Cheung A; Mele S; Chiaruttini G; Crescioli S; Griffin M; Nakamura M; Spicer JF; Tsoka S; Lacy KE; Tutt ANJ; Karagiannis SN
Front Immunol; 2017; 8():1911. PubMed ID: 29375561
[TBL] [Abstract][Full Text] [Related]
6. Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets.
Girolamo F; Dallatomasina A; Rizzi M; Errede M; Wälchli T; Mucignat MT; Frei K; Roncali L; Perris R; Virgintino D
PLoS One; 2013; 8(12):e84883. PubMed ID: 24386429
[TBL] [Abstract][Full Text] [Related]
7. The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas.
Schiffer D; Mellai M; Boldorini R; Bisogno I; Grifoni S; Corona C; Bertero L; Cassoni P; Casalone C; Annovazzi L
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30213051
[TBL] [Abstract][Full Text] [Related]
8. Theranostic impact of NG2/CSPG4 proteoglycan in cancer.
Nicolosi PA; Dallatomasina A; Perris R
Theranostics; 2015; 5(5):530-44. PubMed ID: 25767619
[TBL] [Abstract][Full Text] [Related]
9. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells.
Torisu-Itakura H; Schoellhammer HF; Sim MS; Irie RF; Hausmann S; Raum T; Baeuerle PA; Morton DL
J Immunother; 2011 Oct; 34(8):597-605. PubMed ID: 21904216
[TBL] [Abstract][Full Text] [Related]
10. The Function of NG2/CSPG4-expressing Cells in the Rat Spinal Cord Injury: An Immunoelectron Microscopy Study.
Kabdesh IM; Arkhipova SS; Mukhamedshina YO; James V; Rizvanov AA; Chelyshev YA
Neuroscience; 2021 Jul; 467():142-149. PubMed ID: 34102261
[TBL] [Abstract][Full Text] [Related]
11. A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.
Hoffmann RM; Crescioli S; Mele S; Sachouli E; Cheung A; Chui CK; Andriollo P; Jackson PJM; Lacy KE; Spicer JF; Thurston DE; Karagiannis SN
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331483
[TBL] [Abstract][Full Text] [Related]
12. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
[TBL] [Abstract][Full Text] [Related]
13. CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.
Jordaan S; Chetty S; Mungra N; Koopmans I; van Bommel PE; Helfrich W; Barth S
Biomedicines; 2017 Jun; 5(3):. PubMed ID: 28657611
[TBL] [Abstract][Full Text] [Related]
14. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
[TBL] [Abstract][Full Text] [Related]
15. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
Wang Y; Geldres C; Ferrone S; Dotti G
Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
[TBL] [Abstract][Full Text] [Related]
17. NG2/CSPG4 and progranulin in the posttraumatic glial scar.
Schäfer MKE; Tegeder I
Matrix Biol; 2018 Aug; 68-69():571-588. PubMed ID: 29054751
[TBL] [Abstract][Full Text] [Related]
18. NG2/CSPG4, CD146/MCAM and VAP1/AOC3 are regulated by myocardin-related transcription factors in smooth muscle cells.
Rippe C; Morén B; Liu L; Stenkula KG; Mustaniemi J; Wennström M; Swärd K
Sci Rep; 2021 Mar; 11(1):5955. PubMed ID: 33727640
[TBL] [Abstract][Full Text] [Related]
19. The regulatory mechanisms of NG2/CSPG4 expression.
Ampofo E; Schmitt BM; Menger MD; Laschke MW
Cell Mol Biol Lett; 2017; 22():4. PubMed ID: 28536635
[TBL] [Abstract][Full Text] [Related]
20. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.
Mayayo SL; Prestigio S; Maniscalco L; Rosa G; Aricò A; Maria R; Cavallo F; Ferrone S; Buracco P; Iussich S
Vet J; 2011 Nov; 190(2):e26-e30. PubMed ID: 21482159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
